Glaxo, Boehringer Ingelheim Agree to Expand Anti-HIV Licensing in South Africa
GlaxoSmithKline and Boehringer Ingelheim agreed to allow the widespread manufacture of generic versions of their patented AIDS drugs in South Africa, according to news reports....To view the full article, register now.
Already a subscriber? Click here to view full article